Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Fate Therapeutics (NQ: FATE)
16.85 USD  +0.31 (+1.87%)
Official Closing Price  /  Updated: 5:24 PM EST, Dec 10, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 885,958
Open 16.32
Bid (Size) 16.67 (60)
Ask (Size) 17.19 (4)
Prev. Close 16.54
Today's Range 15.55 - 17.38
52wk Range 4.080 - 17.98
Shares Outstanding 52,858,446
Dividend Yield N/A
Performance
YTD
+167.46%
+167.46%
1 Month
+31.44%
+31.44%
3 Month
+32.05%
+32.05%
6 Month
+46.14%
+46.14%
1 Year
+307.00%
+307.00%
Top News
More News
Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation Read More
from GlobeNewswire News Releases
Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA Read More
from GlobeNewswire News Releases
More News
Read More
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
from GlobeNewswire News Releases
Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy
from GlobeNewswire News Releases
Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500
from GlobeNewswire News Releases
Fate Therapeutics to Present at Upcoming Investor Conferences
from GlobeNewswire News Releases
Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress
from GlobeNewswire News Releases
Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting
from GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results
from GlobeNewswire News Releases
New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies — Factors of Influence, Major Initiatives and Sustained Produ
from GlobeNewswire News Releases
We Did The Math KOMP Can Go To $37
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.